|
|
1414 Raleigh Road, Suite 400 Chapel Hill, NC 27517 USA phone:(919) 913-1030 fax:919-913-1039
|
|
| Symbol |
POZN |
| Exchange |
Nasdaq |
| Founded |
1996 |
| Employees |
|
|
|
| www.pozen.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug therapies for a varity of illness with a focus on migraines. |
 |
| Management |
| John R. Plachetka, Pharm.D., Chairman, President and Chief Executive Officer; Elizabeth A. Cermak, Executive Vice President, Chief Commercial Officer; John G. Fort, M.D., Chief Medical Officer; William L. Hodges, Senior Vice President Finance & Administration and Chief Financial Officer; Everadus Orlemans, Ph.D., Senior Vice President, Product Development |
| |
|
|
|
|
|
|
|
| Keywords |
| sumatriptan, naproxen sodium, non-steroidal, naproxen, osteoarthritis |
|
|
|
| Description |
|
POZEN is pharmaceutical company developing therapeutic advancements in a cost effective manner. POZEN is focused in the pain area of innovative drug development and in creating strategic, high-value partnerships with larger pharmaceutical companies for the commercialization of the company's drug candidates. |
 |
| Products / Services |
POZEN has developed a large product pipeline geared towards migraines.
|
 |
| Market / Customers |
POZEN has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed.
|
 |
| Strategy |
Unlike a traditional pharmaceutical company that operates and funds major functions in-house, POZEN works with strategic partners to execute pre-clinical and clinical studies, develop novel formulations and manufacture the product. Experienced senior staff maintains control over these key functions through effective program management, which includes managing and coordinating these activities, analyzing and interpreting all data and handling FDA interactions. POZEN's business model enables the company to develop its products quickly and efficiently, while minimizing costs.
|
 |
|
|
|
|
|
|